Individuals residing with sort 2 diabetes who use Daonil are inspired to talk with their physician or diabetes healthcare group following affirmation that the medication will likely be discontinued in Australia.
The Therapeutic Items Administration (TGA) has suggested that Daonil (glibenclamide) 5 mg tablets will likely be completely withdrawn from the Australian market from 30 November 2026. The sponsor, Sanofi-Aventis Australia, stated that the discontinuation is because of industrial viability issues.
Daonil is a sulfonylurea drugs used to deal with sort 2 diabetes. Whereas it stays an efficient remedy possibility for some individuals, prescribing has declined over time with the introduction of newer medicines, together with SGLT2 inhibitors, DPP-4 inhibitors and GLP-1 receptor agonists.
Anybody at the moment taking Daonil ought to make an appointment with their physician or diabetes healthcare group effectively earlier than November 2026 to debate appropriate different remedy choices primarily based on their particular person circumstances.
Different sulfonylurea medicines, together with gliclazide, glimepiride and glipizide, stay obtainable in Australia.
